What strategies enable rapid pandemic vaccine development and what trade-offs are involved?

Rapid pandemic vaccine development requires pre-positioning and platform technologies: 1) Platform technologies - mRNA and viral vectors enable rapid antigen sequence insertion without de novo development; reduced from years to months. 2) Pre-clinical preparedness - libraries of characterized vectors, validated manufacturing processes, stockpiled materials. 3) At-risk manufacturing - scale up before Phase 3 completion; government funding absorbs financial risk. 4) Adaptive trial designs - rolling submissions, master protocols, accelerated enrollment. 5) Regulatory agility - emergency use authorization, rolling review, international harmonization. 6) Distributed manufacturing - technology transfer to multiple sites globally. Trade-offs: compressed timelines vs long-term safety data (particularly rare adverse events); emergency use vs full approval confidence; variant adaptation vs verification studies; speed vs supply chain robustness. Lessons from COVID-19 informing pandemic preparedness plans, prototype pathogen approach for priority pathogens, and 100-day vaccine goal.